Evaluation of Endocrine Related Adverse Effects of Non-Endocrine Targeted Pharmaceuticals in Cellular Systems
CONCLUSION: Present data suggest that all tested pharmaceuticals may have potential endocrine disrupting effect, which should be considered when used in pregnancy.PMID:36843259 | DOI:10.2174/1871530323666230224145624 (Source: Endocrine, Metabolic and Immune Disorders Drug Targets)
Source: Endocrine, Metabolic and Immune Disorders Drug Targets - February 27, 2023 Category: Drugs & Pharmacology Authors: Bita Entezari Deniz Bozdag Hande Gurer-Orhan Source Type: research
Evaluation of Endocrine Related Adverse Effects of Non-Endocrine Targeted Pharmaceuticals in Cellular Systems
CONCLUSION: Present data suggest that all tested pharmaceuticals may have potential endocrine disrupting effect, which should be considered when used in pregnancy.PMID:36843259 | DOI:10.2174/1871530323666230224145624 (Source: Endocrine, Metabolic and Immune Disorders Drug Targets)
Source: Endocrine, Metabolic and Immune Disorders Drug Targets - February 27, 2023 Category: Endocrinology Authors: Bita Entezari Deniz Bozdag Hande Gurer-Orhan Source Type: research
Evaluation of Endocrine Related Adverse Effects of Non-Endocrine Targeted Pharmaceuticals in Cellular Systems
CONCLUSION: Present data suggest that all tested pharmaceuticals may have potential endocrine disrupting effect, which should be considered when used in pregnancy.PMID:36843259 | DOI:10.2174/1871530323666230224145624 (Source: Endocrine, Metabolic and Immune Disorders Drug Targets)
Source: Endocrine, Metabolic and Immune Disorders Drug Targets - February 27, 2023 Category: Drugs & Pharmacology Authors: Bita Entezari Deniz Bozdag Hande Gurer-Orhan Source Type: research
Evaluation of Endocrine Related Adverse Effects of Non-Endocrine Targeted Pharmaceuticals in Cellular Systems
CONCLUSION: Present data suggest that all tested pharmaceuticals may have potential endocrine disrupting effect, which should be considered when used in pregnancy.PMID:36843259 | DOI:10.2174/1871530323666230224145624 (Source: Endocrine, Metabolic and Immune Disorders Drug Targets)
Source: Endocrine, Metabolic and Immune Disorders Drug Targets - February 27, 2023 Category: Endocrinology Authors: Bita Entezari Deniz Bozdag Hande Gurer-Orhan Source Type: research
Pantoprazole Induced Stevens-Johnson Syndrome: A case-report
CONCLUSION: This case highlights the possible occurrence of hypersensitivity reactions due to the use of a PPI, which is a widely used medication and a generally well-tolerated drug.PMID:36823997 | DOI:10.2174/1574886318666230224092818 (Source: Current Drug Safety)
Source: Current Drug Safety - February 24, 2023 Category: Drugs & Pharmacology Authors: Mouna Daldoul Ons Charfi Emna Bouattour Houda Hammami-Ghorbe Ahmed Zaiem Samy Fenniche Ghozlane Lakhoua Sihem El Aidli Source Type: research
Pantoprazole Induced Stevens-Johnson Syndrome: A case-report
CONCLUSION: This case highlights the possible occurrence of hypersensitivity reactions due to the use of a PPI, which is a widely used medication and a generally well-tolerated drug.PMID:36823997 | DOI:10.2174/1574886318666230224092818 (Source: Current Drug Safety)
Source: Current Drug Safety - February 24, 2023 Category: Drugs & Pharmacology Authors: Mouna Daldoul Ons Charfi Emna Bouattour Houda Hammami-Ghorbe Ahmed Zaiem Samy Fenniche Ghozlane Lakhoua Sihem El Aidli Source Type: research
Pantoprazole Induced Stevens-Johnson Syndrome: A case-report
CONCLUSION: This case highlights the possible occurrence of hypersensitivity reactions due to the use of a PPI, which is a widely used medication and a generally well-tolerated drug.PMID:36823997 | DOI:10.2174/1574886318666230224092818 (Source: Current Drug Safety)
Source: Current Drug Safety - February 24, 2023 Category: Drugs & Pharmacology Authors: Mouna Daldoul Ons Charfi Emna Bouattour Houda Hammami-Ghorbe Ahmed Zaiem Samy Fenniche Ghozlane Lakhoua Sihem El Aidli Source Type: research
14-day pantoprazole- and amoxicillin-containing high-dose dual therapy for Helicobacter pylori eradication in elderly patients: A prospective, randomized controlled trial
Conclusion: In this trial, we found that 14-day HT had a similar eradication rate to BQT but fewer side effects, which may be better for elderly patients. (Source: Frontiers in Pharmacology)
Source: Frontiers in Pharmacology - February 1, 2023 Category: Drugs & Pharmacology Source Type: research
Nanocracker capable of simultaneously reversing both P-glycoprotein and tumor microenvironment
J Control Release. 2023 Jan 9:S0168-3659(22)00875-6. doi: 10.1016/j.jconrel.2022.12.061. Online ahead of print.ABSTRACTHere, we describe a multidrug-resistant nanocracker (MDRC) that can treat multi-drug resistant (MDR) cancer by recognizing the acidic microenvironment and inhibiting two mechanisms of MDR such as P-glycoprotein (P-gp) and vacuolar-type ATPase (V-ATPase). MDRC is a liposome formulation co-loading pantoprazole (PZ) and paclitaxel (PTX). PZ acts as a chemosensitizer that enhances the MDR cancer treatment effect of PTX by disrupting the pH gradient and inhibiting P-gp. MDRC-encapsulated PZ and PTX have differe...
Source: Cancer Control - January 12, 2023 Category: Cancer & Oncology Authors: Taebum Lee Kyoung Sub Kim Kun Na Source Type: research
Proton pump inhibitors: Understanding the associated risks and benefits of long-term use
CONCLUSION: Higher-quality data is needed to better understand PPI-associated risks of the adverse effects listed above. Until then, clinicians may consider greater vigilance with PPI use; however, the data does not demonstrate a need for wide adoption of de-escalation strategies solely out of safety concerns.PMID:36629265 | DOI:10.1093/ajhp/zxad009 (Source: American Journal of Health-System Pharmacy : AJHP)
Source: American Journal of Health-System Pharmacy : AJHP - January 11, 2023 Category: Drugs & Pharmacology Authors: Kristina M Thurber Ashley O Otto Shawna L Stricker Source Type: research
Proton pump inhibitors: Understanding the associated risks and benefits of long-term use
CONCLUSION: Higher-quality data is needed to better understand PPI-associated risks of the adverse effects listed above. Until then, clinicians may consider greater vigilance with PPI use; however, the data does not demonstrate a need for wide adoption of de-escalation strategies solely out of safety concerns.PMID:36629265 | DOI:10.1093/ajhp/zxad009 (Source: American Journal of Health-System Pharmacy : AJHP)
Source: American Journal of Health-System Pharmacy : AJHP - January 11, 2023 Category: Drugs & Pharmacology Authors: Kristina M Thurber Ashley O Otto Shawna L Stricker Source Type: research
